Showing 7991-8000 of 8465 results for "".
- MELA Sciences Reports the Closing of Its Private Placementhttps://practicaldermatology.com/news/20140728-mela_sciences_reports_the_closing_of_its_private_placement/2459156/IRVINGTON, N.Y., July 25, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced today that it has closed i
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Applicationhttps://practicaldermatology.com/news/20140711-kythera_biopharmaceuticals_announces_fda_acceptance_of_atx-101_new_drug_application/2459173/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficien
- PuraCap Pharmaceutical Introduces EpiCeram 225g Airless Pumphttps://practicaldermatology.com/news/20140711-puracap_pharmaceutical_introduces_epiceram_225g_airless_pump/2459174/PuraCap Pharmaceutical introduced the newest addition to the EpiCeram product line, the EpiCeram 225g Airless Pump. The airless pump gives patients more EpiCeram to treat any size area of atopi
- Galderma Finalizes Expansion in Aesthetic and Corrective Dermatologyhttps://practicaldermatology.com/news/20140710-galderma_finalizes_expansion_in_aesthetic_and_corrective_dermatology/2459175/Galderma S.A. has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra, and Dysport from Valeant Pharmaceuticals International, Inc. “We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and
- Ultherapy Decolletage Treatment Now FDA Clearedhttps://practicaldermatology.com/news/20140707-ultherapy_dcolletage_treatment_now_fda_cleared/2459179/The FDA cleared Ulthera, Inc.'s Ulthera System for the non-invasive treatment of the chest to improve lines and wrinkles of the décolleté. The Ultherapy Décolletage Treatment uses the system's signature imaging and micro-focued ultr
- Aclaris Therapeutics Announces Positive Results from Phase II study of Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/20140702-aclaris_therapeutics_announces_positive_results_from_phase_ii_study_of_seborrheic_keratosis_treatment/2459181/Aclaris Therapeutics, Inc. announced positive results from a Phase II clinical trial of the its lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK). The double-bl
- Merz to Acquire Ulthera, Inc.https://practicaldermatology.com/news/20140630-merz_to_acquire_ulthera_inc/2459184/Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued